1. Adalimumab-induced acute myeloid leukaemia in a patient with Crohn’s disease
- Author
-
Talal Alzahrani, Nejat Naser, Amar R. Jariwala, and Abdulelah Nuqali
- Subjects
Adult ,Male ,musculoskeletal diseases ,Oncology ,medicine.medical_specialty ,Disease ,Core Binding Factor beta Subunit ,03 medical and health sciences ,0302 clinical medicine ,Crohn Disease ,Bone Marrow ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Adalimumab ,Humans ,Chemotherapy-Induced Febrile Neutropenia ,skin and connective tissue diseases ,Beta (finance) ,Gene Rearrangement ,030203 arthritis & rheumatology ,Crohn's disease ,Unexpected Outcome (Positive or Negative) Including Adverse Drug Reactions ,business.industry ,Remission Induction ,Induction Chemotherapy ,General Medicine ,Gene rearrangement ,medicine.disease ,Consolidation Chemotherapy ,Leukemia, Myeloid, Acute ,Increased risk ,Antirheumatic Agents ,030211 gastroenterology & hepatology ,Myeloid leukaemia ,business ,medicine.drug - Abstract
We present a patient with Crohn’s disease under treatment with adalimumab who developed acute myeloid leukaemia (AML) with core-binding factor beta gene rearrangement. This case report emphasises the importance of long-term close follow-up of patients receiving adalimumab because of the increased risk of developing AML and other malignancies.
- Published
- 2019
- Full Text
- View/download PDF